Can Out-Partnering Help Vault Pfizer Over the "Second Cliff"?
Executive Summary
The industry's genericization problem will seriously constrain Big Pharma's ability to pay for late-stage development on all its products. One potential solution is being developed by Pfizer, whose top R&D execs see out-partnering as a way to free up resources for key programs and to expand R&D capacity. In this interview with R&D boss Martin Mackay, Mackay reports that Pfizer is building up a war-chest of out-licensing and partnering candidates, pursuing a wide variety of transactions--including project financing, straight out-licensing and spinoffs. But the extent of Pfizer's long-term commitment to out-partnering still isn't clear.
You may also be interested in...
Pharma R&D: Doing the Same Thing That Didn't Work Before
New data from Credit Suisse and Booz & Co. show that drug research is less novel and even more insular than it was in 2000, with lower percentages of novel targets and biologics in its pipeline. Moreover, Big Pharma has generally licensed less than it should. Nor has Big Pharma been particularly aggressive in copying Big Biotech's focus on developing a robust understanding of underlying disease biology-and reaping Big Biotech's higher approval rates. The cure: companies can significantly improve their odds of success through new approaches outside R&D (with payors, for example) and new capabilities in target selection and validation.
The GSK/Pfizer HIV Venture: Another Sign of Change?
Pfizer and GSK inked an innovative deal to create a jointly owned company focused on HIV therapeutics. The marriage combines GSK's marketing muscle and a stable of established products with Pfizer's newer offerings. While it's unlikely the new venture will unseat rival Gilead as the top player in the HIV market, the deal could be a cash cow for both drug makers, especially if a spin-out ensues.
The GSK/Pfizer HIV Venture: Another Sign of Change?
Pfizer and GSK inked an innovative deal to create a jointly owned company focused on HIV therapeutics. The marriage combines GSK's marketing muscle and a stable of established products with Pfizer's newer offerings. While it's unlikely the new venture will unseat rival Gilead as the top player in the HIV market, the deal could be a cash cow for both drug makers, especially if a spin-out ensues.